Bharat BioTech on Wednesday claimed that its coronavirus vaccine Covaxin has an efficacy of 78 per cent against mild, moderate and severe cases of Covid-19, according to the Phase 3 interim analysis results.

Covaxin has an efficacy of 78% against severe Covid-19 cases: Bharat BioTech

Indian drugmaker Bharat Biotech's coronavirus vaccine, which has been authorized for use in the country, proved safe and produced an immune response in a small group of adults aged 18 to 55, according to a study published in The Lancet medical journal.

Bharat Biotech's COVID-19 shot safe, produced immune response in early human trial: Study

India's Bharat Biotech submitted on Thursday an application for the emergency use of its COVID-19 vaccines in the Philippines, Food and Drug Administration chief Rolando Enrique Domingo said.

India's Bharat Biotech seeks emergency use approval for vaccine in Philippines

The interim findings of phase 1 clinical trial of COVID-19 vaccine Covaxin, indigenously developed by Bharat Biotech in collaboration with the ICMR, showed that it was was well tolerated in all dose groups with no serious or adverse events.

Bharat Biotech's phase 1 trial findings show COVID-19 vaccine well tolerated; no serious adverse events

India's pharmaceutical company Bharat Biotech International Ltd has now, months later, revealed that during Phase 1 of the human trial of COVID-19 vaccine, the company had an adverse event.

Bharat Biotech reveals adverse event during Phase 1 trial of COVID-19 vaccine

India's Bharat Biotech this week offered Brazil a COVID-19 vaccine that is in late-stage clinical trials and a possible technology transfer partnership, a company executive said on Friday.

Bharat Biotech offers Brazil potential coronavirus vaccine

Pharma major Bharat Biotech has announced the development of India’s 1st vaccine candidate for COVID-19, named COVAXIN

Bharat Biotech's indigenous COVID-19 vaccine 'COVAXIN' gets approval